Skip to content

9 results for "Meta-analysis: What did research on DMT find in July 2026?"

Combined DMT-harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers.

Psychopharmacology July 14, 2026 Helena Aicher, Joëlle Dornbierer, Luzia Caflisch et al.

Negative self-referential emotions such as embarrassment and shame play a key role in the psychopathology of psychiatric disorders but are often insufficiently addressed by standard treatments. Psychedelics such as ayahuasca - an Amazonian plant decoction containing the psychedelic N,N-dimethyltryptamine (DMT) and harmala alkaloids, have been proposed to positively modulate self-referential...

Advancing Next-Generation Psychedelic Therapeutics through Selective 5-HT2A Activation, Precision Aerosol Delivery, and Optimized 5-MeO-DMT Treatment Paradigms

ACS Medicinal Chemistry Letters July 10, 2026 Anna C. Renner, Robert B. Kargbo

High Resolution Image Download MS PowerPoint Slide The psychedelic therapeutics field continues to evolve beyond classical hallucinogens toward integrated treatment platforms that combine optimized pharmacology, drug delivery, and clinical implementation. Recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds,...

Proliferative Effects of the Psychedelic N,N-Dimethyltryptamine (DMT) in Human Neural Stem Cells.

ACS Chemical Neuroscience July 9, 2026 José Alexandre Salerno, Elizabeth R. Dominguez, Karina Karmirian et al.

The serotonergic psychedelic N,N-dimethyltryptamine (DMT) produces rapid antidepressant effects in preclinical and early clinical studies. Therapeutic benefits have been linked to sustained neural plasticity, including adult neurogenesis in rodents. Whether brief DMT exposure engages proliferative responses in human neural stem cells (NSCs) remains unresolved. Using human iPSC-derived NSCs, we...

Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression

Journal of Psychopharmacology July 8, 2026 Raynara Bolcont, Fernanda Palhano-Fontes, Handersson Barros et al.

BACKGROUND: -dimethyltryptamine (DMT); however, long-term effects, including broader well-being dimensions, are sparsely explored across populations. AIMS: Investigating whether DMT produces sustained improvements in anxiety, life satisfaction, and quality of life, in both healthy individuals and patients with treatment-resistant depression (TRD). METHODS: In 2 open-label clinical trials, 27...

DMT and Microtubule Coherence Selection: A Testable Model of Informational Throttling in Time Perception

Zenodo (CERN European Organization for Nuclear Research) July 2, 2026 Eugene Catrambone

This paper develops a unified framework linking psychedelic neuropharmacology, microtubule biophysics, and spacetime information theory. Building on prior work (Consciousness and the Scalar Clock, Consciousness as Recursive Spacetime Projection, and Consciousness, Information, and Null Constraints), it proposes that N,N-dimethyltryptamine (DMT) alters subjective time by modulating microtubule...

Reconstituting a two-step pathway for N,N-dimethyltryptamine (DMT) biosynthesis in bacteria

Metabolic Engineering Communications July 1, 2026 Lucas Henrique Junges, Flávia Lada Degaut Pontes, Francisco J. Teles Mota et al.

N,N-dimethyltryptamine (DMT) is a bioactive indole alkaloid that could greatly benefit from scalable, fermentation-based production for research and pharmaceutical applications. In this study, we reconstructed a two-step bacterial pathway converting L-tryptophan to DMT via tryptamine. This involved combining a pyridoxal 5'-phosphate (PLP)-dependent tryptophan decarboxylase from the bacterium...

N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine.

Neuropharmacology July 1, 2026 Anne Nathalia De Sousa-Silva, Clarissa de Almeida Moura, Carina Ioná De Oliveira Torres et al. 1 citation

N,N-dimethyltryptamine (DMT) is an naturally occurring indoleamine with hallucinogenic and antidepressant effects in humans. Here, we compared the effects of DMT and S-ketamine, a fast-acting antidepressant, in helpless mice. To induce helplessness, male single and group-housed mice were exposed to inescapable footshock stress; only helpless animals were subsequently treated with S-ketamine 10...

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review.

Clinical pharmacology and therapeutics July 1, 2026 Tijana Stojanovic, Kent W Nilsson, Robert Fredriksson et al.

Interest in ayahuasca and its main component, N,N-Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited. We therefore systematically examined registered interventional trials of DMT, ayahuasca, and DMT combined with...

DMT und Ayahuasca / DMT and Ayahuasca

Zenodo (CERN European Organization for Nuclear Research) July 1, 2026 Schüller Thomas

DMT und Ayahuasca / DMT and Ayahuasca Eigenständiges bilinguales Vollwerk (DE+EN). Transdisziplinäre wissenschaftliche Übersicht zu DMT und Ayahuasca entlang acht Disziplinen, mit expliziter Geltungsstufen-Kennzeichnung (gesichert / wahrscheinlich / offen). **Schwesterwerke (gleiche Struktur):** FORSCH-0291 (LSD) · FORSCH-0350 (Psilocybin) · FORSCH-0351 (Meskalin) **Theorieanker:** FORSCH-0083...